Pembrolizumab Shows Limited Activity Against Prostate Cancer Pembrolizumab Shows Limited Activity Against Prostate Cancer
Pembrolizumab shows limited activity in selected men with treatment-refractory metastatic castration-resistant prostate cancer (mCRPC), according to findings from the open-label KEYNOTE-199 study.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
More News: Allergy | Allergy & Immunology | Cancer | Cancer & Oncology | Hematology | Prostate Cancer | Study